24 results on '"Tebas, Pablo"'
Search Results
2. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals
3. A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults
4. Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
5. Brief Report
6. Brief Report
7. The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
8. A Randomized Controlled Trial of Palifermin (Recombinant Human Keratinocyte Growth Factor) for the Treatment of Inadequate CD4+ T-Lymphocyte Recovery in Patients with HIV-1 Infection on Antiretroviral Therapy
9. B107 Results of a phase 1 using CCR5 Deficiency with Zinc Finger Nuclease-modified Autologous CD4 T Cells (SB-728-T) in HIV-infected Subjects
10. Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals
11. Disease-Modifying Therapeutic Concepts for HIV in the Era of Highly Active Antiretroviral Therapy
12. Phase I/II Trial of the Anti-HIV Activity of Mifepristone in HIV-Infected Subjects ACTG 5200
13. The Use of HAART Is Associated With Decreased Risk of Death During Initial Treatment of Cryptococcal Meningitis in Adults in Botswana
14. HIV and Cardiometabolic Abnormalities: New Perspectives and Treatment Update
15. Insulin Resistance and Diabetes Mellitus Associated With Antiretroviral Use in HIV-Infected Patients: Pathogenesis, Prevention, and Treatment Options
16. Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney Failure
17. Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides
18. Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid Levels
19. Prevalence, Risk Factors, and Outcomes for Occult Hepatitis B Virus Infection Among HIV-Infected Patients
20. A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm3 After Treatment Interruption Following Antiretroviral Therapy ± Interleukin 2: Results of ACTG A5102
21. Mixed Patterns of Changes in Central and Peripheral Fat Following Initiation of Antiretroviral Therapy in a Randomized Trial
22. Alendronate, Vitamin D, and Calcium for the Treatment of Osteopenia/Osteoporosis Associated With HIV Infection
23. Nonnucleoside Reverse Transcriptase Inhibitor Resistance Among Antiretroviral-Naive HIV-Positive Pregnant Women
24. Insulin Resistance in HIV Protease Inhibitor–Associated Diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.